Regimen doses and schedules
| Regimen . | Induction doses (mg/m2/d × d) . | Postremission therapy . | |||
|---|---|---|---|---|---|
| Ara-C . | Idarubicin . | Fludarabine . | Topotecan3-150 . | ||
| IA | 1500 × 4, CI | 12 × 3 | 0 | 0 | Ara-C, IA × 9-12 mo |
| FA | 1000-2000 × 4-5, bolus | 0 or 12 × 3 | 30 × 4-5 | 0 | Ara-C, FA ± I × 6-12 mo |
| TA | 1000-2000 × 5, bolus | 0 | 0 | 1.5 × 5 CI | TA, or IA, FA, TA × 6-9 m |
| Regimen . | Induction doses (mg/m2/d × d) . | Postremission therapy . | |||
|---|---|---|---|---|---|
| Ara-C . | Idarubicin . | Fludarabine . | Topotecan3-150 . | ||
| IA | 1500 × 4, CI | 12 × 3 | 0 | 0 | Ara-C, IA × 9-12 mo |
| FA | 1000-2000 × 4-5, bolus | 0 or 12 × 3 | 30 × 4-5 | 0 | Ara-C, FA ± I × 6-12 mo |
| TA | 1000-2000 × 5, bolus | 0 | 0 | 1.5 × 5 CI | TA, or IA, FA, TA × 6-9 m |
IA, idarubicin + ara-C; CI, continuous infusion; FA, fludarabine + ara-C; I, idarubicin; TA, topotecan + ara-C.
Cyclophosphamide dose when added to TA was 300 mg/m2 every 12 hours on days 1, 2, and 3.